Leptadenia

Leptadenia: A Comprehensive Reference

1. Identity and Botanical Classification

The name Leptadenia refers to a genus of flowering plants placed within the subfamily Asclepiadoideae of the family Apocynaceae (formerly classified under the now-disbanded family Asclepiadaceae). The genus Leptadenia is comprised of four species: L. pyrotechnica (Forssk.), L. arborea (Forssk.), L. hastata (Pers.), and L. reticulata (Wight & Arn.). Of these, L. reticulata and L. hastata are the two species most studied as dietary supplements and traditional medicines. L. pyrotechnica is also medicinally documented. Each species occupies a distinct ecological niche and geographic range, and each carries its own phytochemical and pharmacological profile. This article addresses all three species in sequence, with greatest depth given to L. reticulata, which is the most comprehensively characterized.

1.1 Leptadenia reticulata (Retz.) Wight & Arn.

Leptadenia reticulata (Retz.) Wight & Arn. (Apocynaceae) is a traditional medicinal plant species widely used to treat various ailments such as tuberculosis, hematopoiesis, emaciation, cough, dyspnea, fever, burning sensation, night blindness, cancer, and dysentery. In Ayurveda it is referred to by many names, including Jivanti, Jivaniya, Jivapushpa, Hemavati, Jivana, Shakashreshtha, Payaswini, Maangalya, and Madhusrava. In Siddha medicine it is known as Keerippaalai. Common vernacular names across India include Dodi (Gujarati and Hindi), Hiriyahalle (Kannada), and Hiranvel (Marathi).

L. reticulata, usually familiar as "Jivanti," is a perennial, extremely branched, twining, and lactiferous climber found in the north and south regions of India; it has a wide range of therapeutic applications documented in practically all classic Ayurvedic scriptures and is regarded as the best vegetable (śreṣṭhaśāka). The plant is also distributed in Mauritius, Madagascar, Sri Lanka, and Burma. L. pyrotechnica is a desert herb with straight stems and mostly leafless, while the other species are twining shrubs and bear leaves.

Its full taxonomic position is: Kingdom Viridiplantae → Phylum Streptophyta → Class Magnoliopsida → Order Gentianales → Family Apocynaceae → Subfamily Asclepiadoideae → Genus Leptadenia → Species L. reticulata.

1.2 Leptadenia hastata (Pers.) Decne

Leptadenia hastata (Pers.) Decne is a commonly used food source and prescribed as a traditional African medicine for treatment of various diseases, such as diabetes, skin disorders, wounds, and ulcers. The plant, belonging to the Asclepiadaceae family, is widely distributed in tropical Africa. It grows in dry savannah and riverine bushland regions of Africa, extending from Senegal, Nigeria, and western Cameroon to Ethiopia, Kenya, and Uganda.

1.3 Leptadenia pyrotechnica (Forssk.) Decne

Leptadenia pyrotechnica (Forssk.) Decne is a wild shrub (family: Asclepiadaceae, sub-family: Apocynaceae), commonly referred to as kheemp in Rajasthan, that grows well in a sandy desert environment (arid-ecosystem) and produces a large amount of biomass, making it a possible source of fibre, food, and medicine. It has common traditional uses in Asia and Africa to cure various serious diseases.

2. Natural Source, Morphology, and Conservation Status

L. reticulata is a perennial herb of Indian origin belonging to the Asclepiadaceae family that has been utilised for its therapeutic properties since ancient times. Morphologically, it is a much-branched twining shrub. Its stems possess a cork-like, deeply cracked bark in mature specimens, while younger stems are glabrous. Leaves are coriaceous, ovate to cordate, 4–7.5 cm long and 2–5 cm wide. Flowers are greenish-yellow and borne in lateral or subaxillary cymes. At present, L. reticulata is a threatened endangered plant because of overexploitation, unscientific harvesting, and habitat loss; the increased demand from pharmaceutical, nutraceutical, and veterinary industries has prompted its large-scale propagation. It is listed as endangered by the Wildlife Institute of India under special habitats and threatened plants of India. The wild resources are unable to meet current demand because of restricted distribution and seasonal availability; hence, cultivation remains the only sustainable alternative. Wild resources of L. reticulata have been depleted by overexploitation, and its low germination percentage, non-availability of genuine plant materials, and lack of knowledge about cultivation practices pose a challenge for commercial cultivation.

3. Common Forms and Preparations

Across both traditional and contemporary use, Leptadenia species are prepared and administered in multiple forms. Traditional preparations most often employ the stems and leaves, though roots appear in certain formulations. Dried herb powders are simmered as decoctions or mixed into ghee, while modern supplements favour encapsulated powders and hydro-alcoholic extracts.

• Decoction (kwātha): Root or whole-plant decoction in water, administered orally. Classical Ayurvedic texts cite a root decoction dose of 20–50 mL for fever and cough.
• Cold infusion (hima): The cold infusion or the fresh juice of the plant is given regularly as a health tonic for the nourishment of the body.
• Herb powder (churna): Dried, pulverised whole plant or specific plant parts, often combined with honey, ghee, or warm milk.
• Paste: The paste of the Jivanti plant is applied over fresh wounds.
• Polyherbal formulations: This plant is one of the major ingredients in many commercial herbal formulations, including Speman, Envirocare, Calshakti, Antisept, and Chyawanprash.
• Leptaden tablets: L. reticulata is a key ingredient in several marketed herbal drugs, including chyawanprash, Speman, and Leptaden. Leptaden is a specific commercial tablet formulation used as a galactagogue.
• Vegetable (shāka): Flowers, leaves, and young shoots are used as a source of nutrition, including during times of famine, due to their valuable nutrients.

4. Traditional and Historical Use

4.1 Ayurvedic Medicine (India, c. 1500 BCE–present)

L. reticulata is well known for its medicinal value from 4500 to 1600 BCE; the oldest scripture in India (the Atharva Veda) mentioned its utility as a strength giver and for maintaining youthful vigour and vitality. The name Jivanti derives from the Sanskrit root jiv, meaning "life," reflecting the plant's revered status.

Rasayana is one of the classes of Ayurveda that improves general bodily health; Rasayana nourishes and rejuvenates the body and increases longevity, memory enhancement, immunomodulation and adaptation. Known as Jivanti in Sanskrit literature, the plant is considered to have the ability to bestow health and vigour, and it is classified as a rasayana and included among the 10 drugs constituting the Jīvanīya gana ("vitalising group").

Classical Ayurvedic physicians documented distinct uses for the plant: Charaka placed it in the Jeevaneeya, Madhura skandha, and Vayasthapana groupings; Sushruta placed it in the Kakolyadi gana; Vagbhata included it in Jeevaneeya. Charaka used Jivanti as an important Rasayana; Sushruta used it for increasing sperm count and enhancing breast milk in lactating mothers; Vagabhatta included Jivanti in Jivaniya Gana.

Traditionally, the plant promotes fitness and vigour, the tone of voice, cures eye diseases, fever, and night blindness, cough, and is used to maintain pregnancy and treat gangrene. It has been used in traditional medicine for treating respiratory disorders, wounds, inflammation, cough, dehydration, tuberculosis, colitis, chickenpox, dysentery, eye diseases, night blindness, fever, and snake bites.

Traditional Ayurvedic preparations and their contexts include:

• The shāka (food preparation) of the plant in the dose of 50 g is beneficial in diarrhoea when taken with curd and ghee, and also for cataracts with ghee; a decoction of Jivanti root should be taken in a dose of 20 mL for relief of burning sensation due to fever.
• The tender stems and fruits are eaten as a vegetable, which helps in improvement of vision; the decoction of the plant is given in a dose of 40–50 mL with honey to treat cough.
• Cold infusion prepared from L. reticulata is given in a dose of 30–40 mL to treat difficulty in micturition and burning micturition; fresh juice or cold infusion of the plant is given to increase breast milk in lactating women.

4.2 Siddha Medicine (South India)

In Siddha medicine, L. reticulata is known as Keerippaalai. It was used within this tradition as a tonic and rejuvenative agent, paralleling its Ayurvedic classification, though specific Siddha textual references have not been independently detailed in the peer-reviewed literature consulted.

4.3 African Traditional Medicine (L. hastata)

L. hastata is a wild plant which belongs to the family Asclepiadaceae and is used as a vegetable by many African populations and as medicine due to its nutritive and therapeutic properties; as a result of its nutritional and medicinal values, the plant has been used for centuries as a remedy for human diseases including hypertension, catarrh, and skin diseases. L. hastata is often used traditionally for hypertension, catarrh, skin diseases, wound healing, prostate complaints, and as an aphrodisiac; in traditional systems of medicine, different parts are used including the leaves, latex, roots, and even the whole plant. Traditional healers use L. hastata to treat many diseases including hypertension, sexual impotence, and trypanosomiasis.

4.4 Desert Traditional Use (L. pyrotechnica)

L. pyrotechnica, commonly referred to as kheemp in Rajasthan, grows in sandy desert environments and is rich in primary and secondary metabolites such as proteins, peptides, fatty acids, phenols, alkaloids, and terpenes, which have been utilised to treat illnesses because of their various pharmacological properties. All parts of L. pyrotechnica are used in traditional medicines; ethnomedicinal uses describe significant antioxidant, anti-inflammatory, antibacterial, anthelmintic, antilipoxygenase, cytotoxic, antitumour, hypolipidemic, and anti-atherosclerotic activity.

5. Key Chemical Constituents and Active Compounds

5.1 L. reticulata

The therapeutic potential of L. reticulata is attributed to the presence of diverse bioactive compounds such as α-amyrin, β-amyrin, ferulic acid, luteolin, diosmetin, rutin, β-sitosterol, stigmasterol, hentricontanol, the triterpene alcohol simiarenol, apigenin, reticulin, deniculatin, and leptaculatin.

Three novel pregnane glycosides — reticulin (1), deniculatin (2), and leptaculatin (3) — were isolated from the aerial parts of L. reticulata; their chemical structures were elucidated by NMR, fast atom bombardment (FAB), and electron ionization mass spectral (EI-MS) data as calogenin-based glycosides with various sugar chain attachments.

L. reticulata is found to be a rich source of many biologically active compounds such as triterpenoids, leptadenol, n-tricontane, cetyl alcohol, β-sitosterol, β-amyrin acetate, lupanol 3-O diglucoside, leptidin, luteolin, diosmetin, stigmasterol, and l-α-tocopherol.

Additional compounds identified include alpha-amyrin, beta-sitosterol, lupeol, and n-triacontane from methanolic extracts, as well as rutin, quercetin, and p-coumaric acid from ethyl acetate extracts of the leaves.

A 2024 metabolomic study using HR-LCMS/MS (Q-TOF) analysis identified 113 compounds from the methanolic extract of L. reticulata. The major chemical classes present include:

• Triterpenoids: α-amyrin, β-amyrin, simiarenol, lupeol
• Sterols: β-sitosterol, γ-sitosterol, stigmasterol
• Pregnane glycosides: reticulin, deniculatin, leptaculatin
• Flavonoids: apigenin, luteolin, diosmetin, rutin, quercetin
• Phenolic acids: ferulic acid, p-coumaric acid
• Aliphatic alcohols and hydrocarbons: hentricontanol, n-tricontane, cetyl alcohol, l-α-tocopherol
• Phytol (a diterpene alcohol)

5.2 L. hastata

L. hastata is reported to contain alkaloids, saponins, phenolic glycosides, tannins, flavonoids, proanthocyanidins, and triterpenes. A 2024 study using UHPLC-Q-TOF-MS tentatively identified 35 compounds in the plant. The leaves are notably rich in essential amino acids, vitamin C, β-carotene, and lycopene. Lupeol has been isolated from the stem bark using column chromatography and confirmed by 1D and 2D NMR spectral data.

5.3 L. pyrotechnica

L. pyrotechnica is rich in primary and secondary metabolites such as proteins, peptides, fatty acids and their esters and alcohols, phenols, alkaloids, simple amines, terpenes, and their derivatives. Cardiac glycosides have been identified from the latex of aerial parts. The green parts of the plant are a valuable source of protein, calcium, dietary fibre, phosphorus, and vitamin C.

6. Proposed Mechanisms of Action

6.1 Galactagogue Activity

The lactogenic (galactagogue) effect of L. reticulata has received considerable mechanistic scrutiny. In an in silico molecular docking study, specific compounds of L. reticulata exhibited strong binding affinity to dopamine D2 receptors (D2R) near the dopamine active site, suggesting potential non-competitive inhibition of dopamine's action, which may enhance prolactin secretion; they also bound to oxytocin receptors (OXTR) with greater affinity than cholesterol, indicating a possible role in facilitating oxytocin-mediated milk ejection; moderate interactions with thyroid hormone receptors TRβ and TRα suggest a supportive influence on lactation through thyroid regulation. The study reveals a possible multi-receptor mechanism by which L. reticulata may promote lactation. These findings remain computational and require validation in wet-lab and clinical settings.

6.2 Anti-Inflammatory and Analgesic Activity

The presence of phenolic compounds and flavonoids in L. reticulata has been reported; phenolics and flavonoids in medicinal plants are responsible for anti-inflammatory activities by inducing free radical scavenging activity and reducing inflammatory cytokines. A decrease in malondialdehyde (MDA) concentration found in animal studies revealed that extracts have the ability to increase the activity of antioxidant enzymes such as SOD, CAT, and GPx in liver and brain tissue, supporting the mechanism involved in anti-inflammatory and analgesic activity of L. reticulata.

6.3 Inflammatory Target Engagement (Network Pharmacology)

SwissTarget Prediction facilitated the identification of potential inflammatory targets; network pharmacology analysis unveiled hub proteins including CCR2, ICAM1, KIT, MPO, NOS2, and STAT3. These computational findings suggest multi-target interactions relevant to inflammatory disease pathways, though no clinical data have confirmed these interactions in humans.

6.4 Antidiabetic Mechanisms

Secondary metabolites of L. reticulata have demonstrated anticancer, anticholesterol, antidiabetic, antiabortifacient, and anti-inflammatory potential. The compound γ-sitosterol, identified in the plant, has separately been shown to have antidiabetic properties in streptozotocin-induced diabetic animal models. Phenolic antioxidants such as rutin and quercetin may contribute to glucose-lowering activity through free radical scavenging and insulin-sensitising mechanisms, though these remain to be confirmed for L. reticulata specifically.

7. Scientific Evidence by Area of Use

7.1 Galactagogue / Lactation Support

This is the most clinically documented application of L. reticulata. The evidence spans animal models, early human controlled trials, and veterinary studies.

Animal studies: Studies by Anjaria and colleagues (1967, 1975) documented lactogenic effects in rats and in dairy animals. Both Leptaden tablets and L. reticulata powder in an equivalent amount produced a significant galactopoietic response in goats, sheep, cows, and buffaloes (Anjaria & Gupta, 1967). The 1975 study specifically documented a lactogenic effect on rats in the Indian Journal of Experimental Biology.

Human/clinical evidence: A controlled trial by Bhandari (1979), published in Indian Practitioner, assessed Leptaden tablets in lactation cases, looking at both infant weight gain and galactagogue effect. A further controlled trial by Kasturi Lal and colleagues (1980) specifically evaluated Leptaden in lactational failure. These early studies are frequently cited in the L. reticulata pharmacology literature, but they are now several decades old, were conducted in India with limited methodological detail available in the current literature, and have not been replicated by large-scale randomised controlled trials meeting modern clinical standards. Most biological studies on L. reticulata are restricted to crude extracts, and many biologically active compounds are yet to be identified in order to base the traditional uses of L. reticulata on evidence-based data.

Evidence strength: Preliminary to moderate — primarily preclinical and older small clinical trials. No rigorous modern RCTs were identified in the literature reviewed. Human evidence is insufficient to draw firm conclusions by contemporary standards.

7.2 Anti-Inflammatory and Analgesic Activity

Preclinical (animal) evidence: A peer-reviewed PMC study evaluated anti-inflammatory, analgesic, and lipid peroxidation inhibition activities in L. reticulata. The anti-inflammatory assay was performed using the λ-carrageenan and formalin-induced paw oedema test; pro-inflammatory mediators (IL-2, IL-6, TNF-α) in serum were analysed by quantitative ELISA; lipid peroxidation inhibition was measured by TBARS assay; analysis of the most active fraction revealed the presence of p-coumaric acid, rutin, and quercetin; the ethyl acetate fraction at 600 mg/kg significantly inhibited λ-carrageenan and formalin-induced paw oedema by 60.59% and 59.24% respectively; and a notable reduction in percentage of writhing (76.25%), induced by acetic acid, signified potent analgesic activity.

Evidence strength: Preclinical only (rodent models). No human clinical trials on inflammation or pain have been identified. These findings cannot be directly extrapolated to human efficacy or dosing.

7.3 Antidiabetic Activity

Preclinical evidence: In a study using streptozotocin-induced diabetic Wistar rats, petroleum ether, ethyl acetate, and ethanol extracts of L. reticulata leaves were administered orally at a dose of 200 mg/kg; metformin was used as the standard antidiabetic drug at 50 mg/kg; the extract showing the highest antidiabetic activity was subjected to column chromatography, leading to the isolation of an active fraction designated Lr-1. Earlier studies reported that the aqueous leaf extract of L. hastata has significant benefits in lowering fasting blood glucose levels, along with antidiabetic and hypoglycaemic activity.

Evidence strength: Preliminary; all evidence is from in vitro and animal (rodent) models. No human clinical trials on blood glucose control have been identified for either L. reticulata or L. hastata.

7.4 Antimicrobial Activity

The plant has been found to exhibit diverse pharmacological activities including antibacterial activity, antifungal activity, and related antimicrobial properties. These activities have been demonstrated primarily in in vitro assays against standard bacterial and fungal strains. L. pyrotechnica possesses antifungal and antibacterial activities coupled with other multifarious uses. Specific minimum inhibitory concentrations and activity spectra have not been uniformly reported across studies, and no clinical antimicrobial trials have been identified.

Evidence strength: In vitro only. No clinical evidence available.

7.5 Anticancer / Cytotoxic Activity

Compounds including β-sitosterol, γ-sitosterol, apigenin, reticulin, deniculatin, leptaculatin, diosmetin, and rutin have been attributed with anticancer properties. Studies examining cytotoxicity have been conducted largely in vitro on cell lines. In silico network pharmacology studies identified STAT3 as a hub target — a protein relevant to cancer cell proliferation and survival — but the scientific basis for the therapeutic potential and mode of action of the active principles of this species remains still undisclosed in terms of in vivo and clinical cancer outcomes.

Evidence strength: Preliminary; in vitro and in silico only. No clinical oncology trials have been reported.

7.6 Antioxidant Activity

The ethyl acetate fraction of L. hastata showed the highest antioxidant activity, with strong DPPH and FRAP values. For L. reticulata, antioxidant capacity has been correlated with its flavonoid and phenolic acid content (rutin, quercetin, p-coumaric acid, ferulic acid, apigenin, luteolin). Antioxidant assays have been conducted using DPPH radical scavenging, FRAP (Ferric Reducing Antioxidant Power), and TBARS methods, consistently showing activity in vitro.

Evidence strength: In vitro only. Clinical antioxidant effects in humans have not been reported.

7.7 Pregnancy Maintenance / Anti-Abortifacient Activity

Traditionally, the plant is used to maintain pregnancy and treat gangrene. Achari and Sinha (1966) clinically trialled the use of Leptaden in treatment of threatened and recurrent abortion. This represents one of the earliest recorded clinical trials with the commercial preparation; however, the methodological quality and full details of this trial are not available in current accessible literature, and it predates modern RCT standards.

Evidence strength: Anecdotal and from a single historical trial with limited accessible detail. Insufficient evidence by modern standards.

7.8 Hepatoprotective Activity

The plant has been found to exhibit hepatoprotective activity in preclinical models. Similar hepatoprotective activity has been observed for L. pyrotechnica. The mechanisms proposed involve antioxidant enzyme upregulation and reduction of lipid peroxidation products in liver tissue. No human clinical data exist.

Evidence strength: Preclinical only.

7.9 Nutritional / Food Use (L. hastata)

Leptadenia hastata leaves are rich in essential amino acids, vitamin C, β-carotene, and lycopene. Its flowers, leaves, and young shoots are used as a source of nutrition during times of famine due to their valuable nutrients. This food use in sub-Saharan Africa is well-documented anthropologically and nutritionally, representing a distinct evidence pathway from pharmacological use.

8. Body Systems and Health Areas Associated with Leptadenia

• Reproductive / Lactation System: Galactagogue effect; traditional use to support breast milk flow; anti-abortifacient use in threatened pregnancy; traditional use for sperm support (L. reticulata).
• Musculoskeletal / Inflammatory: Anti-inflammatory and analgesic activity demonstrated in animal models; traditional use in inflammatory conditions, burning sensations.
• Endocrine / Metabolic: Antidiabetic activity in preclinical models; proposed thyroid hormone receptor interactions relevant to lactation.
• Respiratory: Traditional use for cough, dyspnoea, asthma, and tuberculosis. Anti-asthmatic activity reported in preclinical models.
• Ophthalmological: Traditional use for eye diseases and night blindness; consumed as vegetable for vision maintenance.
• Hepatic: Hepatoprotective activity in preclinical models.
• Immune / Immunomodulatory: Rasayana classification in Ayurveda implies immunomodulatory and adaptogenic properties; modest preclinical evidence available.
• Dermatological: Traditional wound-healing application; antimicrobial activity relevant to skin infections (L. hastata).
• Cardiovascular: Hypotensive action noted with a 50% ethanolic extract of the whole plant (excluding roots) in cat/dog models (Dhar et al., 1974).
• Gastrointestinal: Traditional use for diarrhoea, dysentery, ulcers, and antiulcer properties attributed to constituents.
• Urinary: Traditional use for burning micturition and urinary difficulties.

9. Dosage Forms and Dosages Reported in Studies

The following dosages are cited as reported in the sourced literature and do not represent recommendations:

• Ayurvedic powder (churna): 3–6 g of powder; decoction 50–100 mL.
• Root decoction: 20 mL of root decoction for relief of burning sensation due to fever.
• Root decoction (alternative source): 40–50 mL with ghee to treat fever.
• Decoction for cough: 40–50 mL with honey to treat cough.
• Cold infusion for urinary complaints: 30–40 mL to treat difficulty in micturition.
• Vegetable (shāka) preparation: 50 g food preparation for diarrhoea with curd and ghee.
• Animal study (anti-inflammatory): Petroleum ether, ethyl acetate, and ethanol extracts of leaves at 200 mg/kg body weight orally in rats.
• Animal study (anti-inflammatory/analgesic): Ethyl acetate fraction at 600 mg/kg body weight in rodents.
• Acute toxicity study (oral, rats): Aqueous extract and Leptaden administered orally for three alternate days and three consecutive days to rats, with the dose safely tolerated up to 3.125 g/kg; higher doses led to an increase in mortality.

No standardised, validated human clinical dosage has been established through modern randomised controlled trials for any indication.

10. Safety Considerations

10.1 Acute Toxicity Data

The only formal acute toxicity data identified in the reviewed literature relates to an early animal study: Anjaria and Gupta (1967) reported the toxicity study of L. reticulata aqueous extract; during acute toxicity studies, aqueous extract and Leptaden were administered orally for three alternate days and three consecutive days to rats, with the dose safely tolerated up to 3.125 g/kg; higher doses led to an increase in mortality. No formal NOAEL/LD50 data from rigorous modern toxicological studies were identified in the literature reviewed.

10.2 Conservation and Adulteration Risk

L. reticulata is a threatened endangered plant because of overexploitation, unscientific harvesting, and habitat loss; increased demand from pharmaceutical, nutraceutical, and veterinary industries has prompted efforts for large-scale propagation; however, commercial cultivation is hampered because of the non-availability of genuine planting material. The endangered status of L. reticulata means that commercial preparations may contain substituted or adulterated material. Quality control has become a bottleneck restricting the therapeutic development and utilisation of L. hastata. This concern extends to L. reticulata as well.

10.3 Pregnancy and Hormonal Concerns

The plant has been found to exhibit anti-implantation activity in animal studies, indicating that it may have effects on early embryo implantation. While it is traditionally used as an anti-abortifacient (to prevent abortion), the anti-implantation finding in preclinical models represents a pharmacological complexity that requires caution in interpretation. The proposed dopaminergic and oxytocinergic mechanisms relevant to lactation also imply potential endocrine interactions. No clinical interaction studies have been reported.

10.4 Hypotensive Activity

The 50% ethanolic extract of the whole plant (excluding roots) showed hypotensive action in cat/dog models. This suggests the possibility of blood pressure-lowering effects, which would be relevant for individuals on antihypertensive medications, though no clinical studies confirming this interaction in humans were identified.

10.5 Evidence Gaps and Limitation of Current Safety Data

Most biological studies on L. reticulata are restricted to crude extracts, and many biologically active compounds are yet to be identified in order to base the traditional uses of L. reticulata on evidence-based data. No rigorous clinical safety trials, long-term human toxicology studies, pharmacokinetic/pharmacodynamic profiling in humans, or formal drug-interaction studies were identified in the literature reviewed. The absence of such data means the full safety profile of Leptadenia preparations in humans remains incompletely characterised.

10.6 L. hastata — Anti-Androgenic Activity

An animal study documented anti-androgenic activity of L. hastata, with aqueous extracts of the plant competing with testosterone propionate at receptor sites in castrated immature rats (published in Biotechnologie, Agronomie, Société et Environnement, 2011). In vivo studies showed the antifertility effect of L. hastata leaf extracts, which can be useful for hormonal therapy replacement. These findings indicate potential hormonal activity that warrants further study.

11. Commercial Preparations and Regulatory Context

More than 23 well-defined pharmaceutical products and many herbal-based formulations are available in the market using L. reticulata. Notable commercial formulations include Speman, Envirocare, Calshakti, Antisept, and Chyawanprash. Leptaden, the most studied single-herb commercial preparation, has been the subject of several older Indian clinical trials as a galactagogue. None of these preparations have been evaluated in rigorous placebo-controlled trials meeting contemporary international standards. No approval by the US FDA, EMA, or other major international regulatory bodies for specific disease indications was identified. L. reticulata remains used primarily within the frameworks of Ayurvedic medicine in India and, more recently, as a herbal dietary supplement internationally.

12. Summary of Evidence Quality

The overall body of evidence for Leptadenia species is characterised by a rich traditional history and a growing body of preclinical (in vitro and in vivo animal) research, but remains limited in rigorous human clinical trial data by modern standards. Most biological studies on L. reticulata are restricted to crude extracts, and many biologically active compounds are yet to be identified in order to base the traditional uses of L. reticulata on evidence-based data. The galactagogue application has the most clinical history, backed by early controlled trials and animal data. Anti-inflammatory, antidiabetic, antimicrobial, anticancer, and hepatoprotective activities are supported by preclinical data only. Computational (in silico) studies have proposed mechanistic frameworks for inflammation and lactation, but these require experimental and clinical validation.

References

• Swamy MK et al. (2017). Leptadenia reticulata (Retz.) Wight & Arn. (Jivanti): Botanical, Agronomical, Phytochemical, Pharmacological, and Biotechnological Aspects. Molecules, 22(6), 1019. PMC6152761.
• Dubey SK et al. (2023). A comprehensive review on ayurvedic herb Leptadenia reticulata (Jeevanti): a phytochemistry and pharmacological perspective. Natural Product Research, 38(23). PubMed 37990540.
• A Pharmacological Review: Leptadenia reticulata (Wight & Arn.); Jivanti: the Real Life Giving Plant. PubMed 29341952.
• Sudipta KM et al. (2015). Analgesic, Anti-inflammatory, Anti-lipoxygenase Activity and Characterization of Three Bioactive Compounds in the Most Active Fraction of Leptadenia reticulata. PMC4518123.
• Metabolomic Profiling of Leptadenia reticulata: Unveiling Therapeutic Potential for Inflammatory Diseases through Network Pharmacology and Docking Studies. PMC11054655.
• Zhang J et al. (2024). Qualitative and quantitative chemical analysis of Leptadenia hastata: exploring a traditional African medicinal plant. Frontiers in Chemistry, 12. PMC11066277.
• Souratié et al. (2025). Nutritional Properties and Preventive Potential of Leptadenia hastata (Pers) Decne (Apocynaceae) Against Metabolic Diseases. Food Science & Nutrition. Wiley Online Library.
• Idrees S et al. (2016). Ethnobotanical and Biological Activities of Leptadenia pyrotechnica (Forssk.) Decne.: A Review. African Journal of Traditional, Complementary and Alternative Medicines, 13(4), 88–96. PMC5566157.
• Phytocompounds and pharmacological insights of Leptadenia pyrotechnica: a new perspective on drug discovery. Discover Applied Sciences, 2025.
• Leptadenia reticulata a Rasayana Herbs: A Review. Asian Journal of Plant Sciences, 2010.
• Metabolomic Profiling of Leptadenia reticulata: Unveiling Therapeutic Potential for Inflammatory Diseases (2024). PubMed 38675385.
• Effect of an active fraction isolated from the leaf extract of Leptadenia reticulata on plasma glucose concentration and lipid profile in streptozotocin-induced diabetic rats. ScienceDirect.
• Molecular genetic diversity and biological activity assessment in Leptadenia reticulata from India. ScienceDirect, 2023.
• Atale NM et al. (2026). Unveiling the galactagogue mechanism of Leptadenia reticulata active components: in-silico molecular docking studies. Ayurline: International Journal of Research in Indian Medicine.
• Clinical Study on Plant Galactagogue Worldwide in Promoting Women's Lactation: a Scoping Review. PubMed 34292494.